FFA treatment enhanced the expression of PPARα and decreased the expression of SREBP-1c in FFA-exposed NAFLD model cells, indicating that WVBF activated the PPARα pathway and inhibited the expression of the SREBP-1c/ACC/FAS pathway. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.